Shares of Eli Lilly and Company (NYSE:LLY – Get Free Report) have received a consensus recommendation of “Moderate Buy” from the thirty brokerages that are presently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation, twenty-three have assigned a buy recommendation and two have issued a strong buy recommendation on the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $1,227.7407.
A number of brokerages have issued reports on LLY. Royal Bank Of Canada reaffirmed an “outperform” rating on shares of Eli Lilly and Company in a research note on Thursday, May 21st. Wolfe Research reissued an “outperform” rating and issued a $1,350.00 price objective on shares of Eli Lilly and Company in a research note on Thursday, May 21st. UBS Group restated a “buy” rating on shares of Eli Lilly and Company in a report on Wednesday, March 18th. Cantor Fitzgerald lifted their target price on Eli Lilly and Company from $1,205.00 to $1,230.00 and gave the stock an “overweight” rating in a report on Friday, May 1st. Finally, Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and issued a $1,285.00 price target on shares of Eli Lilly and Company in a research report on Friday, March 6th.
Check Out Our Latest Stock Analysis on LLY
Eli Lilly and Company Price Performance
Eli Lilly and Company (NYSE:LLY – Get Free Report) last announced its earnings results on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.97 by $1.58. The firm had revenue of $19.80 billion during the quarter, compared to analyst estimates of $17.82 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. Eli Lilly and Company’s revenue was up 55.5% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $3.34 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Equities analysts anticipate that Eli Lilly and Company will post 35.8 EPS for the current year.
Eli Lilly and Company Announces Dividend
The firm also recently declared a quarterly dividend, which was paid on Wednesday, June 10th. Shareholders of record on Friday, May 15th were given a $1.73 dividend. The ex-dividend date was Friday, May 15th. This represents a $6.92 annualized dividend and a yield of 0.6%. Eli Lilly and Company’s payout ratio is 24.58%.
Institutional Investors Weigh In On Eli Lilly and Company
Several hedge funds have recently modified their holdings of LLY. Vanguard Group Inc. raised its holdings in shares of Eli Lilly and Company by 1.2% during the fourth quarter. Vanguard Group Inc. now owns 81,965,974 shares of the company’s stock valued at $88,087,193,000 after acquiring an additional 1,006,885 shares during the period. State Street Corp boosted its position in Eli Lilly and Company by 1.8% during the 4th quarter. State Street Corp now owns 35,361,916 shares of the company’s stock worth $38,002,744,000 after acquiring an additional 635,358 shares during the period. Capital Research Global Investors lifted its position in shares of Eli Lilly and Company by 20.9% in the third quarter. Capital Research Global Investors now owns 25,088,371 shares of the company’s stock worth $19,141,787,000 after purchasing an additional 4,332,008 shares in the last quarter. Morgan Stanley increased its stake in Eli Lilly and Company by 2.7% in the 4th quarter. Morgan Stanley now owns 15,593,019 shares of the company’s stock valued at $16,757,510,000 after buying an additional 407,166 shares during the period. Finally, Capital World Investors boosted its stake in shares of Eli Lilly and Company by 0.4% during the 4th quarter. Capital World Investors now owns 15,031,750 shares of the company’s stock valued at $16,154,619,000 after buying an additional 61,851 shares during the period. 82.53% of the stock is owned by hedge funds and other institutional investors.
Eli Lilly and Company News Summary
Here are the key news stories impacting Eli Lilly and Company this week:
- Positive Sentiment: Eli Lilly acquired 4E Therapeutics, adding a non-opioid pain treatment platform that could help diversify the company beyond diabetes and obesity drugs. Lilly buys non-opioid pain drugmaker 4E
- Positive Sentiment: Several reports highlighted Lilly’s ongoing clinical development in oral candidates, Alzheimer’s, and other early-stage programs, reinforcing the company’s deep pipeline and long-term growth potential. Eli Lilly Advances New Oral Candidate With Fresh Phase 1 Bioavailability Study
- Positive Sentiment: Market commentary on the GLP-1 market continued to point to strong long-term demand for obesity and diabetes therapies, supporting the company’s core franchise outlook. Global GLP-1 Receptor Agonist Market Size/Share Worth USD 95.3 Billion by 2035
- Neutral Sentiment: Lilly was also mentioned in broader healthcare and stock-picking articles, but these pieces do not appear to materially change the investment thesis. Top Medical Stocks To Research – June 16th
- Negative Sentiment: European governments, especially Germany, are pushing to tighten medicine pricing rules, and Lilly previously said it would halve a planned $2.7 billion investment in response to the proposed legislation, raising concerns about international growth and margins. Big pharma taps UK playbook to pressure Europe on drug prices
- Negative Sentiment: Separate articles noted that Lilly’s popular GLP-1 drugs are facing new pressure from employer coverage and competitive developments, which could eventually slow demand growth for its biggest products. Eli Lilly’s hottest drugs face a quiet new threat
About Eli Lilly and Company
Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.
Featured Stories
- Five stocks we like better than Eli Lilly and Company
- Flying Under the Radar: Lockheed Martin’s $2.8B Stealth Setup
- Bread’s Comeback Is Real—But Is the Easy Money Gone?
- Ollie’s Stock Has Lagged Despite Earnings Beats—What’s Holding It Back?
- Fox Captures The Living Room With $22B Roku Buy
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.
